Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTXWCZ)

Drug Name
LFM-A13 Drug Info
Synonyms
lfm-a13; 244240-24-2; (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide; SMR001230714; SR-01000075965; 62004-35-7; C11H8Br2N2O2; 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; BiomolKI_000050; LFMA13; BiomolKI2_000056; AC1L1H0E; AC1NS4I5; Lopac0_000650; SCHEMBL51142; BSPBio_001239; BMK1-F2; MLS006010694; MLS002153290; GTPL9262; CHEBI:95065; 2-cyano-N-(2,5-dibromophenyl); MolPort-003-958-579; HMS1362M21; HMS3403M21; HMS2235P16; HMS1990M21; HMS1792M21; BCP12817; 3781AH; s7734; BS0111; ZINC37868487; AKOS024456516; CS-3890
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
54676905
ChEBI ID
CHEBI:95065
TTD Drug ID
DMTXWCZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibrutinib DMHZCPO Mantle cell lymphoma 2A85.5 Approved [2]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [3]
Zanubrutinib DMJWRQP Mantle cell lymphoma 2A85.5 Approved [4]
Pirtobrutinib DMRG1X3 Non-hodgkin lymphoma 2B33.5 Approved [5]
GDC-0853 DMBEL3Q Multiple sclerosis 8A40 Phase 3 [6]
ICP-022 DMU72KL Chronic lymphocytic leukaemia 2A82.0 Phase 3 [7]
Tolebrutinib DML19V6 Multiple sclerosis 8A40 Phase 3 [8]
CC-292 DMJR9H0 Chronic lymphocytic leukaemia 2A82.0 Phase 2 [9]
BMS-986142 DMZB8AJ Rheumatoid arthritis FA20 Phase 2 [6]
LOU064 DME8O5K Chronic idiopathic urticaria EB00.1 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [1]

References

1 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of InnoCare Pharma.
8 Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
9 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)